AKRIBION
LIVE

Serial Number

79361574

Owner

BRAIN Biotech AG

Attorney

Stephen R. Barrese

Filing Date

Oct 26, 2022

Add to watchlist:

No watchlists yet
View on USPTO

AKRIBION Trademark

Serial Number: 79361574 • Registration: 7383363

AKRIBION is a trademark filed by BRAIN Biotech AG on October 26, 2022. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

BRAIN Biotech AG (6 trademarks)

Darmstädter Str. 34-36

Entity Type: 99

Akribion Therapeutics GmbH

Darmstädter Str. 34-36

Entity Type: 98

Trademark Details

Filing Date

October 26, 2022

Registration Date

May 14, 2024

Published for Opposition

February 27, 2024

Goods & Services

Medical services based on biotechnological methods; veterinary services based on biotechnological methods; hygienic and beauty care for human beings and animals based on biotechnological methods; agriculture, horticulture and forestry services, namely, cultivation of agricultural plants for others, horticultural services, and forest habitat restoration, all based on biotechnological methods; regenerative medicine services; medical analysis services for diagnostic and treatment purposes by medical laboratories; medical treatment with cultured cells; medical screening; animal breeding; DNA screening for medical purposes; conducting medical analysis by a medical laboratory for the purpose of the treatment of persons; health care for people; medical analysis services relating to the treatment of persons; medical analysis for the diagnosis and treatment of persons; medical diagnostic testing and analysis services; medical services; medical services in the field of diabetes; medical and health care services; medical and health care services relating to DNA, genetics and genetic testing; medical services for the treatment of the skin; medical services for the treatment of diseases of the human body; medical care and analysis services relating to the treatment of patients; providing information relating to medical services

Testing of materials; quality control for others; biological analysis; biological research; biological laboratory services; biological research and analysis; biological research; clinical research in the field of pharmaceuticals and medical research; research services, namely, scientific research; provision of research services, namely, product research; biomedical research services; industrial research in the field of pharmaceuticals; medical research; pharmaceutical research services; genetic research; research relating to biotechnology; providing information relating to scientific research in the fields of biochemistry and biotechnology; scientific research; technical research, namely, biochemistry research services, biotechnology research services, Research in the field of DNA repair technology, RNA interference technology research, Research in the field of gene editing technology ; chemical research and analysis services; medical, biopharmaceutical and biotechnological research laboratories; research and development of new products for others; computer aided scientific research services; computer aided industrial research services in the field of pharmaceuticals, biotechnology and medicine; biochemical research and analysis; scientific research relating to biology; biotechnological research; biotechnological research relating to industry; scientific and industrial research in the field of gene editing technology, RNA interference technology, DNA repair technology, pharmaceuticals, biotechnology and medicine; scientific research for medical purposes; industrial analysis and research services in the field of gene editing technology, RNA interference technology, DNA repair technology, pharmaceuticals, biotechnology and medicine; medical and pharmacological research services; biological research laboratory services; chemical research laboratory services; chemical research; pharmaceutical research and development; DNA screening for scientific research purposes; research to develop new products; research in the field of gene therapy; cell separation research services; biochemical research and development; research in the field of science provided by engineers; research and development services in the field of chemistry; scientific services, namely scientific investigations for medical and pharmaceutical purposes and medical research relating thereto; scientific research relating to genetics; research and development in the pharmaceutical and biotechnology fields; preparation of biological samples for analysis in research laboratories; research and development in the field of diagnostic preparations; research and development in the field of biotechnology; consultancy in the field of industrial research relating to pharmaceuticals; consultancy in the field of scientific research; analysis of human tissues for medical research; preparation of biological samples for testing and analysis in research laboratories; research and development in the field of microorganisms and cells; biochemical analysis; scientific analysis in the field of biochemistry and biotechnology; technological analysis services, namely technological analysis of gene editing technology, RNA interference technology, DNA repair technology; chemical analysis; scientific research and analysis in the field of biochemistry; analysis in the field of molecular biology; scientific research in the field of genetics; genetic engineering; molecular biology research; scientific research in the field of DNA modification; industrial research in the field of DNA modification ; pharmaceutical research in the field of DNA modification; veterinary research in the field of DNA modification; medical research in the field of DNA modification; veterinary pharmaceutical research in the field of DNA modification; biological testing of materials; biochemical engineering services; biotechnological research relating to agriculture; biotechnological research relating to livestock; analysis services relating to the testing of chemical ingredients in liquids; analysis services relating to the determination of bacterial content in liquids; analysis services relating to the detection of bacterial content in liquids; bacteriological analysis; bacteriological research and analysis; bacteriological research and testing; advice on research in the field of pharmacogenetics; advice on pharmaceutical research and development; consultancy in the field of bacteriological research; consultancy services relating to technological research of gene editing technology, RNA interference technology, DNA repair technology, pharmaceuticals, biotechnology and medicine; consultancy services relating to scientific research; biochemical analysis; biochemical research service; biotechnical research in the industrial sector, namely, biotechnical research in the field of pharmaceuticals; computer-aided industrial analysis services in the field of pharmaceuticals; computer-aided scientific analysis in the field of pharmaceuticals; medical research laboratory services; medical laboratory services; DNA verification for scientific research purposes; conducting chemical research; research in the field of biotechnology; research in the field of medicine; research in the medical field; research on biotechnology; research on chemistry; research and development in the field of bacteriology; research and testing in the fields of bacteriology and virology; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology; research and development services in the field of microorganisms and cells; research work of engineers in the technological field, namely, research in the field of genetic engineering; scientific research work by engineers; research for the development of new products; medical research services; pharmaceutical research; pharmaceutical development; technical research services, namely, product research; scientific services, namely, scientific laboratory services and related scientific research; scientific research in the field of bacteriology; scientific research in the field of pharmacy; scientific research in biology; scientific research in the field of genetics and genetic engineering; scientific research and development of new products for others; scientific research using databases; scientific research services; scientific and technological services, namely, scientific laboratory and software development in the fields of medicine, medical technology, biotechnology, biology, biochemistry and chemistry; research and design of new products in the fields of medicine, medical technology, biotechnology, biology, biochemistry and chemistry; industrial analysis and research services in the field of medicine, medical technology, biotechnology, biology, biochemistry and chemistry; design and development of computer software for use in the field of medicine, medical technology, biotechnology, biology, biochemistry and chemistry; consultancy and information in relation to the aforesaid services

Recycling of waste and trash; air purification and treatment of water; food and drink preservation; processing of biological materials, namely, batch biological treatment services; waste treatment; joining of materials or substances, namely, custom additive manufacturing for others; treatment of hazardous substances, namely, waste, gases and liquids; treatment of materials using biotechnological method, namely, bio-hazard biological decontamination services

Filing History

CHANGE OF OWNER RECEIVED FROM IB
May 28, 2026 CHLD
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 30, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 8, 2024 FICS
FINAL DISPOSITION PROCESSED
Nov 8, 2024 FIMP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 4, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Sep 4, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 4, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 4, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 4, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 4, 2024 COAR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 14, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 14, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
May 14, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 4, 2024 NPUB
NOTIFICATION PROCESSED BY IB
Feb 27, 2024 GPNX
PUBLISHED FOR OPPOSITION
Feb 27, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 7, 2024 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 7, 2024 NONP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 7, 2024 NPUB
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 7, 2024 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 18, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 16, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jan 16, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 20, 2023 GNFN
FINAL REFUSAL E-MAILED
Dec 20, 2023 GNFR
FINAL REFUSAL WRITTEN
Dec 20, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 22, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 22, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 22, 2023 TROA
REFUSAL PROCESSED BY IB
Oct 4, 2023 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 11, 2023 RFCS
REFUSAL PROCESSED BY MPU
Sep 11, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 19, 2023 RFCR
NON-FINAL ACTION WRITTEN
Aug 18, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 10, 2023 DOCK
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 13, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 13, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 13, 2023 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 13, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 13, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 13, 2023 COAR
APPLICATION FILING RECEIPT MAILED
Feb 7, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 3, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 2, 2023 REPR